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Abstract: Traditional concepts of life sciences consider oxidative stress as a fundamental process
of aging and various diseases including cancer, whereas traditional medicine recommends dietary
intake of iron to support physiological functions of the organism. However, due to its strong
pro-oxidative capacity, if not controlled well, iron can trigger harmful oxidative stress manifested
eventually by toxic chain reactions of lipid peroxidation. Such effects of iron are considered to be major
disadvantages of uncontrolled iron usage, although ferroptosis seems to be an important defense
mechanism attenuating cancer development. Therefore, a variety of iron-containing nanoparticles
were developed for experimental radio-, chemo-, and photodynamic as well as magnetic dynamic
nanosystems that alter redox homeostasis in cancer cells. Moreover, studies carried over recent decades
have revealed that even the end products of lipid peroxidation, represented by 4-hydroxynonenal
(4-HNE), could have desirable effects even acting as kinds of selective anticancer substances produced
by non-malignant cells for defense again invading cancer. Therefore, advanced nanotechnologies
should be developed for using iron to trigger targeted lipid peroxidation as an anticancer option of
integrative biomedicine.
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1. Introduction
One of the most challenging health conditions is cancer, and nanotechnology has provided new
opportunities for the development of more efficient treatment procedures. The potential biomedical
benefits of nanoparticles were first suggested in the 1970s, and the era of nanomedicine started at the
turn of this century. Iron containing nanoparticles including iron oxide nanoparticles (IONPs), are
promising tools for anticancer therapies. On the basis of the different oxidation states and crystalline
structures, IONPs comprise magnetite (Fe3O4), maghemite (γ-Fe2O3), and hematite (α-Fe2O3). IONPs
made up of magnetite and maghemite have great biocompatibility with superparamagnetic properties.
Recently, a variety of iron containing nanosystems, as potent agents in anticancer treatment, have been
described in the literature. Iron oxide nanoparticle properties have been reported to be useful for various
biomedical purposes, such are targeted drug delivery, bioimaging, biosensors, and hyperthermia [1],
while some are approved by Food and Drug Administration (FDA) [2,3]. Hence, NanoTherm for
management of glioblastoma and Ferumoxytol for iron deficiency treatment are among the FDA
approved iron oxide containing nanomedicines.
Antioxidants 2020, 9, 191; doi:10.3390/antiox9030191 www.mdpi.com/journal/antioxidants
Antioxidants 2020, 9, 191 2 of 16
Iron has crucial roles in biological systems, such as the immune system, neural system, and
muscular system. Iron also plays an important role in carcinogenesis and altered iron metabolism in
cancer has been well documented [4,5]. Some of the regulatory roles of iron are described below.
2. Iron Regulated Cellular Processes
Iron is an essential nutrient and in the form of ferric ions (Fe3+) is bound to transferrin and
carried through the body. When diferric transferrin is bound to the transferrin receptor the complex
is endocytosed. In the endosome, Fe3+ is reduced to ferrous iron (Fe2+) by a metalloreductase
six-transmembrane epithelial antigen of prostate 3 (STEAP3). This is followed by Fe2+ translocation to
cytoplasm via divalent metal transporter 1 (DMT1), where it enters a transient pool of metabolically
active iron [6]. Intracellularly iron can regulate a variety of processes (Figure 1).
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Another important role of iron is its ability to control mRNA transcription, translation, and 
stability [6]. Low iron concentration promotes hypoxia-inducible factor (HIF) transcription, while 
under conditions of iron repletion they are hydroxylated by the action of HIF prolyl hydroxylase 
domain proteins (PHDs) followed by protein degradation [11]. Furthermore, changes in iron 
concentration regulate mRNA containing an iron responsive element (IRE) in the 3′ and 5′ 
untranslated regions (UTRs). Binding of iron-regulatory protein (IRP) to IRE located in the 3′-UTR of 
the mRNA for transferrin receptor 1 [12] and DMT1 [13] enhances its stability against nuclease attack. 
IRPs also have high affinity towards IRE located at the 5′-UTR of the mRNA for mitochondrial 
aconitase [14] and heavy and light ferritin [15], suppressing its translation. These processes are 
described in detail in an excellent review by Lawen and Lane [6]. Additionally, iron is also involved 
in the control of processing of miRNA precursors through poly(C)-binding protein 2, affecting 
miRNA pathway activity [16].  
In addition to being an essential nutrient, iron can also have potential toxic effects on cells. The 
toxicity is due to their pro-oxidant capacities leading to the generation of reactive oxygen species 
(ROS) that can affect macromolecules and alter cell signaling pathways [17]. It has been well 
recognized that ROS act as a double edge sword and that their activity depends on the concentration 
and type of ROS, as well as on their diffusion distance from the target molecules [18,19]. Excessive 
ROS, based on the amount, have dual effects on tumor growth [20]. Exposure of cervical cancer cells 
to Fe3+ induces ROS formation at lower concentrations and affects oncogene E6/E7 expression [21]. 
Iron and the consequent ROS were shown to modulate nuclear factor-kappa B (NF-κB) signaling 
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under conditions of iron repletion they are hydroxylated by the action of HIF prolyl hydroxylase domain
proteins (PHDs) followed by protein degradation [11]. Furthermore, changes in iron concentration
regulate mRNA containing an iron responsive element (IRE) in the 3′ and 5′ untranslated regions
(UTRs). Binding of iron-regulatory protein (IRP) to IRE located in the 3′-UTR of the mRNA for
transferrin receptor 1 [12] and DMT1 [13] enhances its stability against nuclease attack. IRPs also have
high affinity towards IRE located at the 5′-UTR of the mRNA for mitochondrial aconitase [14] and
heavy and light ferritin [15], suppressing its translation. These processes are described in detail in an
excellent review by Lawen and Lane [6]. Additionally, iron is also involved in the control of processing
of miRNA precursors through poly(C)-binding protein 2, affecting miRNA pathway activity [16].
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In addition to being an essential nutrient, iron can also have potential toxic effects on cells. The
toxicity is due to their pro-oxidant capacities leading to the generation of reactive oxygen species (ROS)
that can affect macromolecules and alter cell signaling pathways [17]. It has been well recognized that
ROS act as a double edge sword and that their activity depends on the concentration and type of ROS,
as well as on their diffusion distance from the target molecules [18,19]. Excessive ROS, based on the
amount, have dual effects on tumor growth [20]. Exposure of cervical cancer cells to Fe3+ induces ROS
formation at lower concentrations and affects oncogene E6/E7 expression [21]. Iron and the consequent
ROS were shown to modulate nuclear factor-kappa B (NF-κB) signaling pathway [22]. By inducing
NF-κB signaling and affecting serum interleukin-6 and serotonin levels, iron exhibits an important
immunomodulatory role [23].
Recently, it was reported that, under both physiological and pathological conditions, iron can
be incorporated into mitochondrial superoxide dismutase (SOD)2. Iron incorporation in SOD2 leads
to a switch in the enzyme activity from antioxidant function of superoxide dismutase to prooxidant
peroxidase. This switch can further contribute to iron toxicity by affecting cellular signaling and
metabolism and eventually the development of cancer [24].
Under normal physiological conditions, superoxide (O2•−) and hydrogen peroxide (H2O2),
derived from a variety of cellular processes, are detoxified by cellular antioxidant systems. The
O2•− is first converted to H2O2, either spontaneously or by the action of SOD, while glutathione
peroxidase (GPX), thioredoxin peroxidase, and catalase further decompose H2O2 to molecular oxygen
and water. However, in an excess of iron, O2•− and H2O2 take part in the Fenton reaction yielding
highly reactive hydroxyl radical (OH•) [25]. Additionally, iron promotes the generation of reactive
nitrogen species (RNS). Both, RNS and OH• promote damage of proteins and lipid peroxidation [26–29].
Depending on the amount of lipid peroxidation products formed, they have either an important
signaling role or exhibit cytotoxic effects for the cells and tissues [30,31]. The consequences of iron
induced lipid peroxidation are described in detail below. Thus, it is evident that maintaining iron and
redox homeostasis is essential.
3. Ferroptosis as a Target for Oncotherapy
Some of the mechanisms of the action of iron containing anticancer therapies account for their
ability to induce ferroptosis (Figure 1). In 2012, ferroptosis was defined as a regulated nonapoptotic
and iron dependent form of cell death [32], which depends on the intracellular concentration of iron as
well as on the amount of ROS and level of lipid peroxidation. The process of ferroptosis is induced by
the inhibition of cysteine import, inactivation of the phospholipid peroxidase glutathione peroxidase 4
(GPX4) activity and glutathione (GSH) depletion, lipid peroxidation, and excessive accumulation of
lipid-based ROS (LO•) [33,34]. Today, different classes of ferroptosis induction compounds (FINs) are
recognized [35]. Those responsible for inducing ferroptosis by depletion of intracellular glutathione
are classified as Class I FINs. Ferroptosis can be triggered by GPX4 inactivation either directly (Class II
FINs) or indirectly (Class III FINs). Additionally, an increase in the LIP via increased activity of heme
oxygenase or directly via iron overload, can also trigger ferroptosis (Class IV FINs) [35].
An abundance of cellular NADPH can determine the sensitivity to ferroptosis as it has an important
role in the elimination of lipid hydroperoxides (LOOH). Nevertheless, the abundance of NADP(H) has
been shown to be inversely correlated with sensitivity of numerous cancer cell lines to ferroptosis [36].
The importance of ferroptosis in the management of neoplastic diseases is well recognized. Cancer
cells harbor an increased iron pool and yet manage to escape ferroptosis, due to the fine balance
between iron and thiols [37]. However, the fact that neoplastic cells have higher requirements of iron
favors ferroptosis as an anticancer process opposing tumor development. Indeed, ferroptosis has been
reported as one of the underlying mechanisms in the inhibition of numerous malignancies [38,39].
IONPs were found to reduce cellular antioxidant defense systems (e.g., activities of SOD, GSH,
and catalase) and to induce ROS generation, lipid peroxidation, and caspase-3 activity promoting
breast cancer cell death [40]. Exposure of human hepatocarcinoma cells to IONPs leads to the formation
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of 8-oxo-2’-deoxyguanosine (8-oxo-dG), and oxidative DNA damage markers. The administration
of alternating magnetic field (AMF) induced magnetic hyperthermia and further contributed to an
elevated 8-oxo-dG level and malignant destruction [41].
One of the adaptive mechanisms of tumor cells is adaptation to reduced levels of oxygen
upregulating the expression of HIF-1. Sanazole, a hypoxic cell radiosensitizer, in a complex with IONP
and the cytotoxic drug Berberine reduced the tumor volume of Dalton lymphoma ascites in a murine
model [42]. The same study suggested that the observed effect was due to the downregulation of HIF-1
and the upregulation of extrinsic apoptotic pathway.
Recently, Sang and coworkers developed ferroptosis amplifier nanodevices for cancer treatment.
Mitochondria targeted the nanophotosensitizer complex containing superparamagnetic IONPs
(SPIONs), and when loaded with Sorafenib, exhibited antitumor activity by inducing ROS formation,
lipid peroxidation, and ferroptosis of therapy resistant epithelial-to-mesenchymal transition cells [43].
The same group later described another mitochondrial membrane that targeted a photosensitive
nanodevice. Black hole quencher-based fluorescence loaded with magnetic IONPs and Sorafenib was
intracellularly disassembled by GSH and anchored to the mitochondrial membrane. Near-infrared
(NIR) laser irradiation triggered ferroptosis and inhibited tumor growth both in vitro and in vivo [44].
A variety of iron containing nanopraticles that improve photodynamic therapy (PDT) effects have been
successfully synthesized [45,46]. Antitumor activity of IONPs can be enhanced by coating, as in the
case of maghemite coated with poly(N,N-dimethylacrylamide) [47].
4. The Lipid Peroxidation Product 4-Hydroxynonenal
In addition to the above-mentioned importance of iron-induced and ROS-mediated lipid
peroxidation and LO• in ferroptosis of neoplastic cells, lipid peroxidation also has an important
role in cell regulation. The peroxidation of polyunsaturated fatty acids (PUFAs) and subsequent
decomposition of lipid hydroperoxides (LOOH) leads to formation of reactive aldehydes, among which
4-hydroxynonenal (4-HNE) is of particular interest. Namely, due to its bioactive properties, 4-HNE can
either directly or indirectly affect macromolecules and modulate cellular processes and function, thus,
resembling bioactivities of ROS [48,49]. Known also as a second messenger of free radicals, which
interferes with bioactivities of various cytokines, 4-HNE acts in concentration-dependent and cell-type
dependent manners [50,51]. Generally speaking, if present at low, physiological concentrations, 4-HNE
mostly acts as a growth regulating factor affecting proliferation, differentiation, and antioxidant
capacities of the cells, whereas its presence at higher supraphysiological levels usually induces
apoptosis or even necrosis. One of major reasons for such multifunctional bioactivities of 4-HNE is
its high affinity to bind to proteins, modulating their structure and function and forming a kind of
reservoir of 4-HNE-proten adducts, which are hardly metabolized and could offer an explanation for
the adverse effects of very different medical remedies, either synthetic or of natural origin [49,52–54].
It is commonly believed that 4-HNE possesses mutagenic and carcinogenic affects, and thus resembles
negative carcinogenic activities of free radicals. However, due to the altered lipid metabolism and
hypoxia, cancer cells develop different antioxidant capacities as compared with their counterpart
non-malignant cells, but eventually that makes them more susceptible to the cytotoxic effects of
4-HNE [55–57]. Complex interactions between invading cancer and surrounding tissue can lead to
the enhanced production of 4-HNE by normal, stromal, and especially inflammatory cells. Then,
elevated 4-HNE acts as a kind of anticancer substance [58,59]. The fact that all rapidly proliferating
cells, including those that are malignant, require higher levels of iron than is needed for the resting cells,
while the iron-triggered and self-catalyzed chain reaction of lipid peroxidation generates 4-HNE, could
present novel opportunities to use iron and other transition metals as potential anticancer substances,
especially if packed in the form of relatively stable micro- or nanoparticles [60].
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5. Iron-Containing Nanoparticles in Oncotherapy
Ferroptosis, as a promising mechanism for the demise of cancer cells, has become a promising
strategy in cancer nanomedicine. Due their advantages, iron-containing nanoparticles are used in
numerous nanomedicine strategies in oncology (Figure 2).Antioxidants 2020, 9, x FOR PEER REVIEW 5 of 16 
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Chemodynamic therapy (CDT) with a high specificity towards a tumor microenvironment (TME)
is a promising strategy for the management of cancer. The anticancer properties of CDT are due to
their ability to promote conversion of endogenous H2O2 via Fenton reaction into •OH triggering
lipid peroxidation and ferroptosis of cancer cells [61,62]. In recent years, an effort has been made
to develop nanoparticles with encapsulated iron for ferroptosis assisted CDT. Conjugated polymer
nanoparticles (CPNPs) containing iron(III) and targeted to endothelin-B receptors selectively trigger
ferroptosis of melanoma cells with no significant effect on normal cells [63]. Wang and colleagues
developed redox- and light-responsive (RLR) nanoparticles that contained iron and were programmed
to degrade and self-activate in an acidic environment with excessive glutathione, as is the case for a
tumor microenvironment (TME). The constructed RLR nanoparticles were loaded with doxorubicin
(DOX) and modified with iRGD peptide that binds to αvβ3 integrins. Such nanoparticles showed
specificity in targeting integrin overexpressing cancer cells as compared with normal cells [64]. Further
specificity towards cancer cells has been confirmed in the in vivo tumor model.
Magnetic hyperthermia is another important application of iron containing nanoparticles for cancer
treatment. Magnetic hyperthermia is based on the effects of AMF on the magnetization properties
of iron causing a heat release in the surrounding space. The simultaneous action of chemodynamic
therapy with magnetic-photo hyperthermia has an inhibitory effect on tumor progression, as reported
for Fe3O4-Pd Janus nanoparticles [65]. The mechanism of anticancer activity included both amplified
magnetic-photo heating, as well as elevated ROS production and ferroptosis of cancer cells. Furthermore,
nanotheranostic potential of iron oxide nanoparticles was shown for α-Fe2O3 nanoparticles coated with
ultrasmall gold (Au) nanoseeds. The α-Fe2O3 with Au nanoparticles resembled good photothermal
efficacy and upon irradiation, with low laser power, yielded ROS generation and DNA damage,
suppressing tumor growth [66]. Compared to ferromagnetics, superparamagnetic iron oxide
nanoparticles generate more heat and are extensively used in cancer therapy. Superparamagnetic
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properties of iron oxide nanoparticles have shown promising results in the hyperthermia treatment of
solid tumors such as prostate cancer [67,68] and glioblastoma [69,70]. Impressively, almost complete
glioblastoma regression was observed after multiple applications of magnetic hyperthermia [70]. For
further reading on the medical applications of SPIONs, a comprehensive review has been published
last year [71]. Xiong and colleagues have recently developed a nanosystem containing DOX, FeCl3,
and tannic acid. Photothermal excitation triggered drug release from the nanosystem, while laser
irradiation promoted ROS generation, lipid peroxidation, ferroptosis, reduced intracellular glutathione
(GSH) level, and inhibited tumor progression, as shown both in vitro and in vivo on an ER+ breast
carcinoma model [72].
The ability of polydopamine nanoparticles to chelate metal ions has been used in developing
ultrasmall poly(ethylene glycol) (PEG)-modified polydopamine nanoparticles containing either Fe2+
or Fe3+ [73]. Such nanoparticles showed potent anticancer activity by ferroptosis via induction of ROS
formation and lipid peroxidation and inhibition of GPX4 activity. Furthermore, the specific design of
the study identified that Fe2+ and Fe3+ ion preferred anticancer mechanisms. Nanoparticles containing
Fe2+ had a preference for ROS induced ferroptosis, whereas those containing Fe3+ had a preference for
lipid peroxidation-dependent ferroptosis [73].
Recently, nanozymes with iron containing nanoparticles have been demonstrated to be good
tools for cancer therapy. Nanozymes are nanomaterials exhibiting intrinsic enzyme-like properties.
The peroxidase-like activity of iron containing nanoparticles was first reported in 2007 [74]. To date,
iron containing nanozymes with various enzyme mimetic properties have been reported, such as
catalase, peroxidase, or SOD-like activities. The classification of nanozymes, together with their
catalytic properties and application, have been recently described in an excellent review by Huang and
colleagues [75]. One example of nanozymes used for the anticancer strategies, is the recently developed
nanozymes biodegradable in the acidic environment with peroxidase-like catalytic activity having
microwave enhancing dynamic therapy (MEDT) and microwave thermal therapy (MTT) effects [76].
Microwave irradiation accelerated •OH generation in the tumor microenvironment. Novel nanozymes,
under microwave irradiation, were able to locally increase temperature, as well as promote ROS
formation, in particular •OH, leading to malignant cell destruction and inhibition of a tumor.
The scientific community is continuously making efforts to improve current, or developing novel
more efficient, nanosystems for oncotherapy. Table 1 highlights the recent animal studies with iron
nanodevices for cancer therapy by altering cellular redox homeostasis.
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Table 1. Recent animal studies with variety of iron containing nanoparticles for cancer therapy by altering cellular redox homeostasis.
Tumor Type Animal Tumor Model Type of Nanoparticles Reported Therapy Effect Ref.
Breast cancer Breast tumor xenograftmouse model
RLR nanoparticle composed
of Fe3O4 nanoparticles and a
nanoflower-like MnO2 shell
Chemodynamic therapy
Nanoparticles are degraded under acidic
environment and excessive GSH yielding
accelerated ROS production and
tumoricidal effect.
[64]
Breast cancer 4T1 tumor-bearing mice Fe3O4-Pd Janusnanoparticles (JNPs)
Simultaneous
magnetic-photo
hyperthermia and
chemodynamic therapy
Dual exposure of nanoparticles to AMF and
laser irradiation induces enhanced
temperature and ROS generation that are via
Fenton reaction converted to OH•.
[77]
Breast cancer 4T1 tumor-bearing mice
α-Fe2O3 nanoparticles coated
with ultrasmall gold
nanoseeds
Magnetic resonance
imaging, photothermal
therapy and
radiosensitization
Upon NIR irradiation nanoparticles showed
enhanced photothermal therapy and
sensitized radiotherapy by inducing ROS
formation and tumor inhibition.
[66]
Breast cancer 4T1 tumor-bearing mice
Ultrasmall PEG-modified
polydopamine nanoparticles
containing Fe2+/3+
Chemotherapy,
Ferroptosis therapy
Fe2+ containing nanoparticles induce ROS
dependent ferroptosis while Fe2+ containing
nanoparticles induce lipid
peroxidation-dependent ferroptosis.
[73]
Breast cancer 4T1 tumor-bearing mice
Nanoparticles
porphyrin-based
metal–organic framework
and MnFe2O4 nanoparticles
as the nanoenzyme
Enhanced Photodynamic
Therapy
Nanodevice exhibits catalase-like and
GPX-like activity, In the tumor, upon
irradiation, continuously promotes ROS
formation via Fenton reaction, and reduces
GSH modulating tumor microenvironment.
[78]
Breast cancer 4T1 tumor-bearing mice
Silica nanoparticles with
MnO2 nanoparticles
and FeCO
Synergistic Gas therapy
(GT) and chemodynamic
therapy (CDT)
Under acidic environment MnO2 promotes
ROS that further triggers decomposition of
FeCO into CO.
[79]
Breast cancer MCF-7 tumor-bearingmice
Nanogel loaded with
magnetic IONPs and
10-hydroxy camptothecin
Enhanced
photothermal-chemotherapy
Nanogel represents a good anticancer drug
delivery system and can also serve as
nanocarrier for photothermal therapy due to
its absorption at NIR region. Furthermore,
magnetic IONPs in the presence of
macrophages promote ROS formation.
[80]
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Table 1. Cont.
Tumor Type Animal Tumor Model Type of Nanoparticles Reported Therapy Effect Ref.
Breast cancer 4T1 tumor-bearing mice
Nanosystem containing
Fe(OH)3 modified
upconversion nanoparticles
Synergetic chemo- and
photodynamic therapy
INR irradiation promotes ROS formation in
cancer cells. [81]
Breast cancer 4T1 tumor-bearing mice IONPs modified with glucoseoxidase and polydopamine Photothermal therapy
NIR irradiation induces heat generation and
formation of H2O2. H2O2 is then via Fenton
reaction converted to OH• inducing
apoptosis of cancer cells.
[82]
Breast cancer 4T1 tumor-bearing mice
ROS nanoreactor based on
core-shell-structured iron
carbide nanoparticles
Magnetic Resonance
Imaging Guided Cancer
Therapy
In the acidic tumor microenvironment Fe2+
are released in acidic environments where,
via Fenton reaction, generate OH• and
inhibit tumor.
[83]
Breast cancer 4T1 tumor-bearing mice
FeOOH nanoparticles coated
with poly(norepinephrine)
and loaded with
artemisinin (Art)
Photothermal-chemical
combination therapy
Exposure to NIR promotes heat generation
and synchronous release of iron ions and Art
in the acidic tumor microenvironment
promotes generation of ROS and subsequent
generation of OH• via Fenton reaction
having high toxicity for tumor and low for
normal tissue.
[84]
Breast cancer 4T1 tumor-bearing mice
Mitochondrial membrane
targeted nanophotosensitizer
complex containing SPION
and sorafenib
Ferroptosis as cancer
therapy
Activated nanoparticles consume GSH,
induce excessive ROS production and
release SPION and sorafenib, promoting
ferroptosis. Efficacy was also shown for the
drug resistant in vitro model.
[43]
Breast cancer 4T1 tumor-bearing mice
Mitochondrial membrane
targeted nanophotosensitizer
complex containing magnetic
IONPs and sorafenib
Ferroptosis as cancer
therapy
Activated nanoparticles downregulate
GPX-4 and xCT inducing ferroptosis. [44]
ER+ breast cancer MCF7 tumor xenograftmodel Balbc
Drug-organics-inorganics
self-assembled (DFTA)
nanosystem with DOX, FeCl3
and tannic acid
Chemotherapy,
Photothermal therapy and
Ferroptosis therapy
Photothermal excitation triggers DOX
release, activates SOD-like reaction and
reduces GSH through excessive
ROS production.
[72]
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Table 1. Cont.
Tumor Type Animal Tumor Model Type of Nanoparticles Reported Therapy Effect Ref.
Glioma Ectopic gliomatumor-bearing mice Fe3O4-IR806 superparticles
Photothermal-photodynamic
therapy
Photothermal conversion efficacy upon NIR
irradiation was enhanced and promoted
excessive ROS formation exhibiting
tumor toxicity.
[85]
Hepato-cellular
carcinoma
H22-tumor bearing mice
and HepG2
tumor-bearing nude mice
Nanozymes containing
Fe-metal organic framework
nanoparticles
Microwave enhancing
dynamic therapy,
Microwave thermal therapy
Microwave irradiation promotes excessive
ROS formation, in particular OH•, inducing
cell death. In the presence of gold
nanoclusters, the same can have application
in imaging and microwave thermal therapy.
[76]
Hepato-cellular
carcinoma
H22-tumor bearing mice
and HepG2
tumor-bearing nude mice
PEG-modified nanoparticles
loaded with photosensitizer
and MnFe2O4 and silica
upconversion nanoparticles
Photodynamic therapy
Loading efficiency of photosensitizer is
increased NIR irradiation activates
luminescence form upconversion
nanoparticles yielding activation of
photosensitizer and consequent ROS
formation that take part in Fenton reaction
eliciting tumoricidal effect.
[46]
Lung
adenocarcima
A549 tumor-bearing
nude mice
Modified IONPs with
β-lapachone encapsulated in
the nanostructure formed by
H2O2-responsive
polyprodrug and
pH-responsive polymer
(LaCIONPs)
Chemo/chemodynamic
combination therapy
Acidic environment of tumor cells triggers
LaCIONPs decomposition triggering
excessive H2O2. H2O2 further via Fenton
reaction produces OH• and also activates the
release of drug eliciting tumoricidal effect.
[86]
Prostatic cancer PC3 tumor-bearingnude mice
γ-Fe2O3 with copper
sulfide shell
Photothermal Therapy,
Magnetic Hyperthermia
and Photodynamic Therapy
NIR exposure and magnetic stimulation
promotes heat generation and ROS
formation with tumoricidal effects.
[68]
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6. Approaches to Attenuate the Effects of Iron-Containing Nanoparticles on Healthy Cells
and Tissue
In addition to the beneficial anticancer activities of iron-containing nanoparticles, one should
also consider the potential adverse effects for healthy tissue. Toxicological potential of a variety
nanoparticles [87], including the ones containing iron, have been reported [88]. Most of the metal
nanoparticles induce generation of ROS and affect cellular redox mechanisms that could lead to
their genotoxicity [89]. Iron-containing nanoparticles were shown to induce oxidative stress and
dermal toxicity in vitro [88]. Janus Fe3O4-TiO4 nanoparticles, a potential agent for magnetic resonance
imaging and PDT, when used at a higher dose (25 µg/cm2), alter cellular redox homeostasis of normal
hepatic cells inducing lipid peroxidation while decreasing cell viability and ATP levels. However,
if used at a lower dose (6.25 µg/cm2), such effects are not observed [90]. Additionally, particle size
and different coatings on their surface can be detrimental for their activity [91]. Therefore, it is of
crucial importance to develop strategies that will attenuate the adverse effects of iron containing
nanoparticles for healthy tissue. Moreover, one should bear in mind that cytotoxicity of nanomaterials
is dose dependent and concentrations that showed beneficial effects in vitro could have no effect
or adverse effects in vivo and could also differ depending on the target tissue. Supplementation
with antioxidants, such as thymoquinone, showed promising effects both in vitro and in vivo [92].
Indocyanine green used for PDT was found to be more stable and safer for healthy tissue when loaded
to 3-aminopropyltrimethoxysilane coated cationic SPIONs and used as PTT and PDT dual therapy [77].
Functionalization of the IONPs surface with small molecules or polymers could improve IONPs
stability and biocompatibility [1,93]. Functionalization can also improve or add new properties to
IONPs such as antioxidant and antimicrobial activity [94], enabling thermal therapy [93], or promoting
ROS-induced anticancer activity [95].
7. Conclusions
Iron is necessary for numerous physiological processes but could also be an important trigger
of oxidative stress, especially of lipid peroxidation, thus, contributing either to carcinogenesis or to
toxicity of anticancer treatments. Hence, ferroptosis acts as a potential natural anticancer defense
mechanism that uses iron to generate ROS and lipid peroxidation and eventually destroy cancer cells.
Furthermore, recent findings indicate that the end products of lipid peroxidation, notably 4-HNE,
could be generated by non-malignant cells as a defense mechanism against cancer complementary
to ferroptosis. Although numerous promising iron-containing nanoparticles were developed for
experimental radio-, chemo-, and photodynamic, as well as magnetic dynamic nanosystems that
induce oxidative stress and ferroptosis, they do not exploit selective cytotoxicity of 4-HNE as a
potentially novel anticancer activity principle. Namely, binding of 4-HNE to (extra)cellular proteins
could result in persistent lipid peroxidation selectively destroying cancer cells due to the differences
in lipid metabolism and antioxidant systems between cancer and non-malignant cells. Therefore,
nanosystems should be developed that use iron to trigger ferroptosis and target lipid peroxidation as
anticancer options of integrative biomedicine utilizing the benefits of advanced nanotechnologies and
of natural anticancer defense mechanisms of the host.
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